Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction

Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association

(2019) Janani Rangaswami et al.   CIRCULATION

Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis

(2018) Csaba P Kovesdy et al.   EUROPEAN HEART JOURNAL

Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists

(2018) Marco Trevisan et al.   EUROPEAN JOURNAL OF HEART FAILURE

Associations of serum potassium levels with mortality in chronic heart failure patients

(2017) Mette Aldahl et al.   EUROPEAN HEART JOURNAL

Serum potassium in patients with chronic heart failure: once we make a U-turn where should we go?

(2017) Bertram Pitt et al.   EUROPEAN HEART JOURNAL

Potassium lowering agents: Recommendations for physician and patient education, treatment reappraisal, and serial monitoring of potassium in patients with chronic hyperkalemia

(2017) Bertram Pitt et al.   PHARMACOLOGICAL RESEARCH

Hyperkalemia After Initiating Renin–Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project

(2017) Ghassan Bandak et al.   Journal of the American Heart Association

Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality

(2017) Julio Núñez et al.   CIRCULATION

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

(2016) Piotr Ponikowski et al.   EUROPEAN HEART JOURNAL

Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia

(2016) Patrick Rossignol et al.   EUROPEAN JOURNAL OF HEART FAILURE

The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure

(2016) Bertram Pitt et al.   Expert Opinion On Drug Safety

Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure

(2015) Lauren B. Cooper et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin–angiotensin system inhibitors in the community increases the risk of acute kidney injury

(2015) Tobias Dreischulte et al.   KIDNEY INTERNATIONAL

Incident hyperkalemia may be an independent therapeutic target in low ejection fraction heart failure patients: Insights from the HEAAL study

(2014) P. Rossignol et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

A New Equation to Estimate Glomerular Filtration Rate

(2013) Andrew S. Levey et al.   ANNALS OF INTERNAL MEDICINE

Incidence, Determinants, and Prognostic Significance of Hyperkalemia and Worsening Renal Function in Patients With Heart Failure Receiving the Mineralocorticoid Receptor Antagonist Eplerenone or Placebo in Addition to Optimal Medical Therapy

(2013) Patrick Rossignol et al.   Circulation-Heart Failure

The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial

(2013) Timothy J. Collier et al.   EUROPEAN HEART JOURNAL

Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry

(2013) Aldo P. Maggioni et al.   EUROPEAN JOURNAL OF HEART FAILURE

Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies

(2012) Stuart J. Pocock et al.   EUROPEAN HEART JOURNAL

Serum Potassium Levels and Mortality in Acute Myocardial Infarction

(2012) Abhinav Goyal et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

(2010) Faiez Zannad et al.   NEW ENGLAND JOURNAL OF MEDICINE